10.01.03
The National Institutes of Health (NIH), Bethesda, MD, has awarded Dr. William Cefalu, at the Pennington Biomedical Research Center of Louisiana State University, a research grant to evaluate the use of Chromax® chromium picolinate supplementation in people with type 2 diabetes. According to Dr. Cefalu, this study will use “gold standard” techniques to evaluate carbohydrate metabolism in human subjects with type 2 diabetes and will also use techniques to evaluate the specific mechanism by which it may work. “Based on the large numbers of subjects to be evaluated, this study has the potential to specifically address the role of chromium picolinate in diabetes, and follow up on the positive observations seen in the obese animal models,” he said. Currently there are 13 published human clinical studies demonstrating significant efficacy of chromium picolinate supplementation in diabetes and metabolic syndrome.